Pharmaceuticals company SMS Pharmaceuticals announced Q3FY25 results Revenue from operations in Q3FY24 was Rs 173.35 crore, up 7% YoY, driven by strong demand. In Q3FY25, gross margins improved to 39%, up 729bps YoY and 870bps sequentially. EBITDA margins for Q3FY25 stood at 19%, up 120bps YoY and 316bps sequentially. PAT rose to Rs 18.24 crore, up 341bps YoY and 336bps sequentially, with PAT margin expanding to 11%. P. Vamsi Krishna, Executive Director, said: “We continued to see healthy volume demand for our products, supported by notable client wins across key APIs an encouraging sign for future growth. While we are navigating pricing pressures, our focus on profitability has kept margins strong and steady. Looking ahead, we expect to end the year on a strong note. The second phase of our backward integration project, set to begin commercial production in March 2025, will drive margin expansion from FY26 onwards. Our CMO business is also set to take off and contribute to our performance. Additionally, our capacity expansion remains on track, enabling us to scale volumes across our key APIs.” Result PDF